Welcome and thank you for considering the New England Journal of Medicine (NEJM) as a venue for your work. As the oldest continuously-published medical journal, our mission since 1812 has been to ...

Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation ...

Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered ...

Infants were eligible if they were born between 32 weeks 0 days’ and 35 weeks 6 days’ gestation, had been admitted to a neonatal unit, and had intravenous access that had been established for ...

This phase 2 trial showed that a single subcutaneous dose of L9LS at the highest dose tested (300 mg) provided protective efficacy of 69.9% against P. falciparum infection and 77.4% against ...

In the year after the elimination of a waiver requirement to prescribe buprenorphine, the number of prescribers increased above the anticipated value, but the number of persons who received the ...

We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β 0 /β 0, β 0 /β 0-like, or non–β 0 /β ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats ...

Disclosure forms provided by the authors are available with the full text of this editorial at NEJM.org. From the Global Health Division, Bill and Melinda Gates Foundation (J.M.M.), and the Fred ...

Dr. Jamie Aron (Emergency Medicine): A 27-year-old man was evaluated at this hospital because of leg weakness. The patient had been in his usual state of health until 3 days before the current ...

The autologous cellular therapy exagamglogene autotemcel is generated by editing an erythroid-specific enhancer of BCL11A. Could another site be edited unintentionally? This study gauged the ...